Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00425386 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Kidney Cancer

Interventions

DRUG: erlotinib hydrochloride
DRUG: sunitinib malate
PROCEDURE: biopsy

Sponsor

OHSU Knight Cancer Institute

Collaborators

[object Object]